IQVIA (NYSE:IQV) Price Target Cut to $240.00 by Analysts at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its target price decreased by JPMorgan Chase & Co. from $279.00 to $240.00 in a report released on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

IQV has been the topic of several other reports. The Goldman Sachs Group lowered their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Truist Financial lowered their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday. Finally, Robert W. Baird cut their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Stock Performance

IQV stock opened at $212.96 on Tuesday. The firm has a 50 day simple moving average of $232.84 and a 200 day simple moving average of $229.54. IQVIA has a 52 week low of $190.20 and a 52 week high of $261.73. The stock has a market cap of $38.65 billion, a P/E ratio of 27.95, a P/E/G ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP acquired a new stake in IQVIA in the third quarter worth $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA during the 3rd quarter worth approximately $28,000. Versant Capital Management Inc lifted its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the 2nd quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the 2nd quarter worth approximately $29,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.